Entellus Medical initiates enrollment in rhinosinusitis study

Entellus Medical, a medical technology company, has started enrollment in the FinESS Registry, a prospective, post-approval registry study designed to assess subject rhinosinusitis symptomatic status of up to 500 patients treated with FinESS sinus treatment over time. Up to 25 medical practices in the US may participate in this registry.

The objective of the registry is to assess subject rhinosinusitis symptomatic status at pre-treatment, six months and 12 months post-treatment following FinESS sinus treatment using data collected from validated, self-administered quality of life surveys.

FinESS sinus treatment is a less-invasive treatment option to break the cycle of chronic rhinosinusitis, the company said. It is for patients whose symptoms persist or return, despite antibiotics and steroids or for patients who do not need, want or can’t have extensive sinus surgery. Unlike extensive sinus surgery FinESS does not require the removal of delicate bone or sinus tissue, resulting in shorter treatment and recovery time with very little pain or bleeding, according to Entellus Medical.

Paul Cink, principal investigator of the FinESS Registry, said: This registry will provide significant symptomatic status data across a broad community sample, which will help us understand the impact of this innovative treatment.